ArticleCell communication and signaling : CCS2026
The IQGAP1-claudin cell junction axis in cisplatin-induced epithelial damage.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The IQGAP1-Claudin4-JNK Signaling Axis as a Differential Biomarker in Renal Cell Carcinoma.Clinical and translational science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysfunction of epithelial cell contacts associates with a myriad of human diseases. Cisplatin is an effective antineoplastic agent where it interferes with DNA replication in proliferating cells, but it causes kidney epithelial damage by unclear mechanism(s). We hypothesized that cisplatin displaces the cell-contact proteins IQGAP1-claudin complex in the kidney tubules, potentially causing epithelial cell dissociation implicated in kidney damage. Employing a multifaceted approach, using mutant analyses and a low cisplatin dose, this hypothesis was tested in cell culture and iqgap1−/− murine model. Cisplatin inhibited cell proliferation and migration in an IQGAP1-dependent manner, displaced IQGAP1 from cell junctions and differentially altered the expression level of key junctional markers, including claudins 2/4/8. Similar effects were observed in animal models where cisplatin treatment and loss of IQGAP1 displayed additive effects, particularly in the distal tubules, suggesting secretion and transport defects as underlying factors. These alterations are accompanied by suppression of Akt1/PKB survival and ERK1/2 proliferation signals and activation of JNK-GSK3αβ stress and inflammatory signal. These findings present IQGAP1-claudin axis as a biomarker and therapeutic targets in kidney damage and pave the way for formulating new analogs that eliminate cisplatin adverse side effects while preserving its antineoplastic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.